Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

Arcadia Biosciences, Inc.: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Armistice Capital, LLC amended its Schedule 13G filing covering its stake in Arcadia Biosciences, Inc., per SEC accession 0001172661-26-005252. The amendment updates the investment firm's previously reported beneficial ownership position in the agricultural biotechnology company. Schedule 13G filings are required of investors holding passive stakes above 5% of a class of securities, so the revision signals a change in Armistice's reported holdings. The filing did not disclose a specific change in share count or percentage in the headline. Investors will watch for further 13G or 13D filings to determine whether Armistice is accumulating, trimming or maintaining its position in Arcadia.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Armistice Capital, LLC, Arcadia Biosciences, Inc.